BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 16477219)

  • 1. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients.
    Takada Y; Haga H; Ito T; Nabeshima M; Ogawa K; Kasahara M; Oike F; Ueda M; Egawa H; Tanaka K
    Transplantation; 2006 Feb; 81(3):350-4. PubMed ID: 16477219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients.
    Guo L; Orrego M; Rodriguez-Luna H; Balan V; Byrne T; Chopra K; Douglas DD; Harrison E; Moss A; Reddy KS; Williams JW; Rakela J; Mulligan D; Vargas HE
    Liver Transpl; 2006 Apr; 12(4):560-5. PubMed ID: 16555313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of living donor liver transplantation for Egyptian patients with hepatitis C (genotype 4)-related cirrhosis.
    Yosry A; Esmat G; El-Serafy M; Omar A; Doss W; Said M; Abdel-Bary A; Hosny A; Marawan I; El-Malt O; Kamel RR; Hatata Y; Ghali A; Sabri H; Kamel S; El-Gbaly H; Tanaka K
    Transplant Proc; 2008 Jun; 40(5):1481-4. PubMed ID: 18589133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation.
    Shiffman ML; Stravitz RT; Contos MJ; Mills AS; Sterling RK; Luketic VA; Sanyal AJ; Cotterell A; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2004 Oct; 10(10):1248-55. PubMed ID: 15376308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course.
    Gallegos-Orozco JF; Yosephy A; Noble B; Aqel BA; Byrne TJ; Carey EJ; Douglas DD; Mulligan D; Moss A; de Petris G; Williams JW; Rakela J; Vargas HE
    Liver Transpl; 2009 Dec; 15(12):1872-81. PubMed ID: 19938138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age.
    Selzner N; Girgrah N; Lilly L; Guindi M; Selzner M; Therapondos G; Adeyi O; McGilvray I; Cattral M; Greig PD; Grant D; Levy G; Renner EL
    Liver Transpl; 2008 Dec; 14(12):1778-86. PubMed ID: 19025914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis.
    Bozorgzadeh A; Orloff M; Abt P; Tsoulfas G; Younan D; Kashyap R; Jain A; Mantry P; Maliakkal B; Khorana A; Schwartz S
    Liver Transpl; 2007 Jun; 13(6):807-13. PubMed ID: 17539001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up.
    Jain A; Singhal A; Kashyap R; Safadjou S; Ryan CK; Orloff MS
    Transplantation; 2011 Aug; 92(4):453-60. PubMed ID: 21799468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients.
    Schmeding M; Neumann UP; Puhl G; Bahra M; Neuhaus R; Neuhaus P
    Liver Transpl; 2007 May; 13(5):687-92. PubMed ID: 17457911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma.
    Lo CM; Fan ST; Liu CL; Chan SC; Ng IO; Wong J
    Br J Surg; 2007 Jan; 94(1):78-86. PubMed ID: 17016793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is recurrent hepatitis C worse with living donors?
    Kuo A; Terrault NA
    Curr Opin Organ Transplant; 2009 Jun; 14(3):240-4. PubMed ID: 19395968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.
    de Arias AE; Haworth SE; Belli LS; Burra P; Pinzello G; Vangeli M; Minola E; Guido M; Boccagni P; De Feo TM; Torelli R; Cardillo M; Scalamogna M; Poli F
    Liver Transpl; 2009 Apr; 15(4):390-9. PubMed ID: 19326408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence.
    Sandhu L; Sandroussi C; Guba M; Selzner M; Ghanekar A; Cattral MS; McGilvray ID; Levy G; Greig PD; Renner EL; Grant DR
    Liver Transpl; 2012 Mar; 18(3):315-22. PubMed ID: 22140013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors.
    Gaglio PJ; Malireddy S; Levitt BS; Lapointe-Rudow D; Lefkowitch J; Kinkhabwala M; Russo MW; Emond JC; Brown RS
    Liver Transpl; 2003 Oct; 9(10):1028-35. PubMed ID: 14526396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of hepatitis C histological recurrence rates and patient survival between split and deceased donor liver transplantation.
    Lawal A; Ghobrial R; Te H; Artinian L; Eastwood D; Schiano TD
    Transplant Proc; 2007 Dec; 39(10):3261-5. PubMed ID: 18089367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation.
    Thuluvath PJ; Yoo HY
    Liver Transpl; 2004 Oct; 10(10):1263-8. PubMed ID: 15376301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of hepatitis C infection after liver transplantation.
    Gane EJ; Portmann BC; Naoumov NV; Smith HM; Underhill JA; Donaldson PT; Maertens G; Williams R
    N Engl J Med; 1996 Mar; 334(13):815-20. PubMed ID: 8596547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation.
    Garcia-Retortillo M; Forns X; Llovet JM; Navasa M; Feliu A; Massaguer A; Bruguera M; Fuster J; Garcia-Valdecasas JC; Rimola A
    Hepatology; 2004 Sep; 40(3):699-707. PubMed ID: 15349910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients.
    Hayashi PH; Forman L; Steinberg T; Bak T; Wachs M; Kugelmas M; Everson GT; Kam I; Trotter JF
    Liver Transpl; 2003 Jul; 9(7):737-40. PubMed ID: 12827562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma.
    Takada Y; Ueda M; Ito T; Sakamoto S; Haga H; Maetani Y; Ogawa K; Kasahara M; Oike F; Egawa H; Tanaka K
    Liver Transpl; 2006 Jun; 12(6):912-9. PubMed ID: 16489583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.